Innate Pharma Partners With Sobi To Advance Lacutamab Toward Phase 3, Targets Accelerated Approval Filing In Sézary Syndrome
Benzinga Newsdesk 2 months ago
News
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndromeMarkus Jensen appointed Chief Medical Officer, bringing
- Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome
- Markus Jensen appointed Chief Medical Officer, bringing leadership continuity to execute TELLOMAK-3 and to prepare for upcoming IPH4502 development milestones